drugset
drugset / Trial / NCT04288778

A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes

NCT04288778 ↗

Phase 4 Completed 276 enrolled Johnson & Johnson Private Limited
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess safety of canagliflozin + metformin hydrochloride immediate Release (IR) fixed-dose combination.

Timeline

Start
2020-11-25
Primary completion
2022-07-26
Completion
2022-07-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 50 mg Oral
Subject Metformin Small molecule 500 mg Oral
Subject Metformin Small molecule 1000 mg Oral

Indications

diabetes mellitus